Communiqués Emergent BioSolutions Inc.

Actions

EBS

US29089Q1058

Produits pharmaceutiques

Marché Fermé - NYSE 22:00:02 15/09/2026			Varia. 5j.	Varia. 1 janv.
6,360 ^USD	-0,31%		+6,00%	-48,54%

15/09	Emergent BioSolutions Inc. annonce une cérémonie d'inauguration pour célébrer le redémarrage de la production et la croissance de son site de Canton	CI
03/09	Emergent BioSolutions rachete 75 millions de dollars de notes seniors non garanties echeance 2028	MT

Communiqués

15/09	Media Advisory: Emergent to Host Ribbon Cutting Ceremony at Canton Manufacturing Facility	GL
03/09	Emergent BioSolutions Completes Repurchase of $75 Million Aggregate Principal Amount of Senior Unsecured Notes	GL
01/09	Emergent BioSolutions Awarded Contract Modification Valued at Approximately $24 Million for CYFENDUS® (Anthrax Vaccine Adsorbed, Adjuvanted)	GL
31/08	Emergent BioSolutions Awarded Government of Canada Standing Offer for NARCAN® Nasal Spray	GL
31/08	Emergent BioSolutions Reinforces Commitment to Opioid Overdose Education and Preparedness on International Overdose Awareness Day	GL
05/08	Emergent Biosolutions: Q2 Earnings Snapshot	AQ
05/08	Emergent BioSolutions Commits to Cross-Sector Collaboration Against Biological Threats in an Evolving Global Security Environment	GL
05/08	Emergent BioSolutions Commits to Cross-Sector Collaboration Against Biological Threats in an Evolving Global Security Environment	AQ
05/08	Emergent BioSolutions Reports Second Quarter 2026 Financial Results	GL
22/07	Emergent BioSolutions to Report Second Quarter 2026 Financial Results on August 5, 2026	GL
29/06	Emergent BioSolutions Secures Contract Modification Valued at Approximately $52.7 Million for ACAM2000® (Smallpox and Mpox (Vaccinia) Vaccine, Live) from the U.S. Government	GL
05/06	Emergent BioSolutions Supports Victoria's Voice Foundation's National Naloxone Awareness Day to Help Save Lives from Opioid Overdose	AQ
04/06	Emergent BioSolutions Supports Victoria’s Voice Foundation’s National Naloxone Awareness Day to Help Save Lives from Opioid Overdose	AQ
28/05	Emergent BioSolutions Receives $64.5 Million Contract Modification for BAT® [Botulism Antitoxin Heptavalent (A, B, C, D, E, F, G) – (Equine)] to Support U.S. Biodefense Strategy	GL
20/05	Emergent BioSolutions to Participate in Upcoming Investor Conferences	GL
18/05	Emergent BioSolutions Receives Saudi Food and Drug Authority Approval for ACAM2000® [Smallpox and Mpox (Vaccinia) Vaccine, Live]	GL
30/04	Emergent Biosolutions: Q1 Earnings Snapshot	AQ
30/04	Emergent BioSolutions Reports First Quarter 2026 Financial Results	GL
30/04	Emergent BioSolutions Receives Approval from Singapore Health Sciences Authority for Expanded Indication of ACAM2000® (Smallpox and Mpox (Vaccinia) Vaccine, Live) to Include Mpox	GL
29/04	Emergent BioSolutions Secures Long-Term Strategic Manufacturing Contract with SAB Biotherapeutics to Advance Type 1 Diabetes Candidate, SAB-142	GL
29/04	Emergent BioSolutions Partners with Professional Baseball Player Davis Schneider to Raise Awareness of NARCAN® Nasal Spray Among Canadians and Help Save Lives	GL
29/04	Davis Schneider's brother died of an overdose. The Blue Jay says naloxone can save others	AQ
28/04	Emergent BioSolutions and Substipharm Biologics Announce Strategic Manufacturing Partnership to Support Japanese Encephalitis Vaccine in the United States	GL
28/04	Emergent BioSolutions and Substipharm Biologics Announce Strategic Manufacturing Partnership to Support Japanese Encephalitis Vaccine in the United States	AQ
16/04	Emergent BioSolutions to Report First Quarter 2026 Financial Results on April 30, 2026	GL